Aragón educa : revista del Museo Pedagógico de Aragón

Se habla de las actividades y prácticas llevadas a cabo en el Centro de Arte y Naturaleza de la Fundación Beulas de Huesca. Se explican las acciones llevadas a cabo en el centro y fuera de él para la promoción y conocimiento de dos de sus colecciones: Beaulas-Serrate y arte y naturaleza.AragónDirección General de Política Educativa; Avda. Gómez Laguna, 25, planta 2; 50009 Zaragoza; Tel. +34976715416; Fax +34976715496ES

Aragón educa : revista del Museo Pedagógico de Aragón

Se habla del desarrollo creciente de la función educativa en los museos de Aragón. Se evidencia el acercamiento del patrimonio cultural que ofrecen, sirviendo de apoyo en el desarrollo curricular de diversas materias. Se resumen las actividades, los talleres, las exposiciones y las visitas guiadas que se ofrecen en los museos más importantes de Aragón. Se destaca el aumento de las exigencias de calidad de sus usuarios debido a la extensión de los medios audiovisuales, las tecnologías de la información y de la comunicación.AragónDirección General de Política Educativa; Avda. Gómez Laguna, 25, planta 2; 50009 Zaragoza; Tel. +34976715416; Fax +34976715496ES

DataSheet_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.pdf

BackgroundManaging the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.MethodsWe designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg once a day for 14 days), could reduce the incidence of respiratory insufficiency in COVID-19. 48 cytokines were correlated with clinical outcome.ParticipantsPatients admitted due to COVID-19 infection with mild disease.ResultsUp to 92 were included. Mean age was 64 ± 17, and 28 (30%) were female. 11 (22%) patients in the control arm and 6 (12%) in the experimental arm reached an OSCI grade of 5 or higher (p = 0.29). Unsupervised analysis of cytokines detected two clusters (CL-1 and CL-2). CL-1 presented a higher risk of clinical deterioration vs CL-2 (13 [33%] vs 2 [6%] cases, p = 0.009) and death (5 [11%] vs 0 cases, p = 0.059). Supervised Machine Learning (ML) analysis led to a model that predicted patient deterioration 48h before occurrence with a 85% accuracy.ConclusionsRuxolitinib plus simvastatin did not impact the outcome of COVID-19. Cytokine profiling identified patients at risk of severe COVID-19 and predicted clinical deterioration.Trial registrationhttps://clinicaltrials.gov/, identifier NCT04348695.</p

Table_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.xlsx

BackgroundManaging the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.MethodsWe designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg once a day for 14 days), could reduce the incidence of respiratory insufficiency in COVID-19. 48 cytokines were correlated with clinical outcome.ParticipantsPatients admitted due to COVID-19 infection with mild disease.ResultsUp to 92 were included. Mean age was 64 ± 17, and 28 (30%) were female. 11 (22%) patients in the control arm and 6 (12%) in the experimental arm reached an OSCI grade of 5 or higher (p = 0.29). Unsupervised analysis of cytokines detected two clusters (CL-1 and CL-2). CL-1 presented a higher risk of clinical deterioration vs CL-2 (13 [33%] vs 2 [6%] cases, p = 0.009) and death (5 [11%] vs 0 cases, p = 0.059). Supervised Machine Learning (ML) analysis led to a model that predicted patient deterioration 48h before occurrence with a 85% accuracy.ConclusionsRuxolitinib plus simvastatin did not impact the outcome of COVID-19. Cytokine profiling identified patients at risk of severe COVID-19 and predicted clinical deterioration.Trial registrationhttps://clinicaltrials.gov/, identifier NCT04348695.</p